PROTAC development gains momentum, but clinical performance is poor
Pharmaceutical Technology
FEBRUARY 13, 2023
This makes early R&D less risky, as many lead compounds are discontinued due to inadequate pharmacokinetic profiles and require excessively high dosages to be pharmaceutically active. Both degraders, ARV-110 (bavdegalutamide) and ARV-766, are being developed by Arvinas.
59 
Let's personalize your content